


**Amendments to the Claims**

Claims 1-21 (canceled)

22. (currently amended) A method of treating a condition responsive to a tyrosine kinase inhibitor, ~~which comprises~~ the method comprising administering to a patient in need of treatment a therapeutically-effective amount of a compound ~~as claimed in Claim 16~~ of formula (Ia):



(Ia)

wherein R is hydrogen, methyl, or ethyl;  
or a pharmaceutically-acceptable salt thereof.

23. (new) The method of Claim 22, wherein the compound is selected from the group consisting of:

3-[3,5-dimethyl-4-(3-oxo-3-piperazin-1-ylpropyl)-1H-pyrrol-2-ylmethylene]-1,3-dihydroindol-2-one,

3-[3,5-dimethyl-4-[3-oxo-3-(4-ethyl)piperazin-1-ylpropyl]-1H-pyrrol-2-ylmethylene]-1,3-dihydroindol-2-one,

and pharmaceutically-acceptable salts thereof.


24. (new) The method of Claim 22 wherein the compound is 3-[3,5-dimethyl-4-(3-oxo-3-piperazin-1-ylpropyl)-1H-pyrrol-2-ylmethylene]-1,3-dihydroindol-2-one or a pharmaceutically-acceptable salt thereof.

25. (new) The method of any one of Claims 22 to 24, wherein the condition responsive to a tyrosine kinase inhibitor is a proliferative disorder.

26. (new) The method of any one of Claims 22 to 24, wherein the condition responsive to a tyrosine kinase inhibitor is a form of cancer.

27. (new) The method of any one of Claims 22 to 24, wherein the condition responsive to a tyrosine kinase inhibitor is selected from the group consisting of acute myeloid leukemia, small cell lung cancer, prostate cancer, gastrointestinal cancer, breast cancer, brain cancer, restenosis, and growth of a solid tumor.

28. (new) A method of treating a condition responsive to a tyrosine kinase inhibitor, the method comprising administering to a patient in need of treatment a therapeutically-effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier and a compound of formula (Ia):



(Ia)

wherein R is hydrogen, methyl, or ethyl,  
or a pharmaceutically-acceptable salt thereof.

29. (new) The method of Claim 28, wherein the compound is selected from the group consisting of:

3-[3,5-dimethyl-4-(3-oxo-3-piperazin-1-ylpropyl)-1H-pyrrol-2-ylmethylene]-1,3-dihydroindol-2-one,

3-[3,5-dimethyl-4-[3-oxo-3-(4-ethyl)piperazin-1-ylpropyl]-1H-pyrrol-2-ylmethylene]-1,3-dihydroindol-2-one,

and pharmaceutically-acceptable salts thereof.

30. (new) The method of Claim 28 wherein the compound is 3-[3,5-dimethyl-4-(3-oxo-3-piperazin-1-ylpropyl)-1H-pyrrol-2-ylmethylene]-1,3-dihydroindol-2-one or a pharmaceutically-acceptable salt thereof.

31. (new) The method of any one of Claims 28 to 30, wherein the condition responsive to a tyrosine kinase inhibitor is a proliferative disorder.

32. (new) The method of any one of Claims 28 to 30, wherein the condition responsive to a tyrosine kinase inhibitor is a form of cancer.

33. (new) The method of any one of Claims 28 to 30, wherein the condition responsive to a tyrosine kinase inhibitor is selected from the group consisting of acute myeloid leukemia, small cell lung cancer, prostate cancer, gastrointestinal cancer, breast cancer, brain cancer, restenosis, and growth of a solid tumor.